The trajectory of Sildenafil presents a interesting case for investors in the drug sector. While initially a blockbuster success, producing huge profits, the intellectual property lapse and the subsequent flood of generic competitors have considerably changed earnings. This raises questions about the future sustainability of similar drug innovat… Read More